UPDATE: Intellia Therapeutics (NTLA) PT Lowered to $83 at Morgan Stanley (correction)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts NTLA Hot Sheet
Price: $12.25 +3.29%
Rating Summary:
22 Buy, 9 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
22 Buy, 9 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
(Updated - November 3, 2022 2:00 PM EDT)
Morgan Stanley analyst Terence Flynn lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $83.00 (from $84.00) while maintaining a Overweight rating.
The analyst comments "NTLA reported 3Q22 results, but focus remains on pipeline progress, where NTLA will present new '2002 HAE data Nov 12 and likely incremental '2001 ATTR-CM data Nov 5. We see the upside valuation case for NTLA as compelling."
You May Also Be Interested In
- Stanley Black & Decker (SWK) PT Raised to $135 at Jefferies
- Marriott International (MAR) PT Lowered to $141 at Jefferies
- Flutter Entertainment (FLUT) PT Raised to $96 at BTIG
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
